RUNX1 and neoplasm: RUNX1 has been shown to facilitate AXIN1 mediated suppression of β-catenin by inhibiting estrogen-dependent signaling, specifically in ER+ disease [98], where low expression of AXIN1 was associated with low RUNX1 expression, unveiling a potential mechanism for RUNX1-mediated tumor suppression.